TTrialPathMatch Me to Trials
← Back to trials
RecruitingClinical Stage IVB Gastric Cancer AJCC v8Metastatic Gastric AdenocarcinomaMetastatic Malignant Neoplasm in the Peritoneum

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.

Sponsor: City of Hope Medical Center

You may qualify if…

  • ✓ Patients must have failed first-line systemic therapy (fluorouracil, leucovorin calcium, oxaliplatin \[FOLFOX\] with or without immunotherapy, or other fluoropyrimidine and platinum-based therapy)
  • ✓ Prior immunotherapy allowed
  • ✓ Up to 4 cycles of second-line therapy allowed if no progression is documented
  • ✓ Documented informed consent of the participant and/or legally authorized representative
  • ✓ Assent, when appropriate, will be obtained per institutional guidelines
  • ✓ Agreement to allow the use of archival tissue from diagnostic tumor biopsies
  • ✓ If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • ✓ Age: ≥ 18 years

You may not qualify if…

  • ✕ Intolerance to taxanes
  • ✕ Bowel obstruction requiring exclusive total parenteral nutrition
  • ✕ Any history of, or current, brain or subdural metastases
  • ✕ Life expectancy \< 3 months
  • ✕ Treatment with therapeutic oral or IV antibiotics within 14 days prior to day 1 cycle 1 of treatment
  • ✕ Patients receiving prophylactic antibiotics are eligible, provided the signs of active infection have resolved
  • ✕ Any prior malignancy except adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for two years
  • ✕ History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents (taxanes, etc.)

Where it's recruiting

Source: ClinicalTrials.gov · NCT06675136 · last updated 2026-11-10

Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab fo · TrialPath